Published in Mol Cancer Ther on July 16, 2012
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res (2015) 0.96
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One (2013) 0.91
The design and characterization of receptor-selective APRIL variants. J Biol Chem (2012) 0.86
Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer (2015) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Critical role for Daxx in regulating Mdm2. Nat Cell Biol (2006) 2.96
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
P53 and radiation responses. Oncogene (2003) 2.52
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
A meta-analysis of CDH1 C-160A genetic polymorphism and gastric cancer risk. DNA Cell Biol (2011) 2.15
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell (2008) 2.04
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther (2003) 1.92
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther (2002) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol (2006) 1.88
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Tissue-specific induction of p53 targets in vivo. Cancer Res (2002) 1.79
BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther (2002) 1.72
TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets (2010) 1.65
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem (2004) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol (2008) 1.58
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell (2004) 1.54
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
A common mechanism for mitotic inactivation of C2H2 zinc finger DNA-binding domains. Genes Dev (2002) 1.53
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
Invariant NKT cells are required for airway inflammation induced by environmental antigens. J Exp Med (2011) 1.51
Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity (2003) 1.51
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (2002) 1.45
Leber's hereditary optic neuropathy is associated with the T12338C mutation in mitochondrial ND5 gene in six Han Chinese families. Ophthalmology (2010) 1.44
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 1.41
Mcl-1: a gateway to TRAIL sensitization. Cancer Res (2008) 1.41
Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis (2009) 1.40
Heliothis virescens and Manduca sexta lipid rafts are involved in Cry1A toxin binding to the midgut epithelium and subsequent pore formation. J Biol Chem (2002) 1.38
Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther (2005) 1.38
Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther (2004) 1.38
Single amino acid mutations in the cadherin receptor from Heliothis virescens affect its toxin binding ability to Cry1A toxins. J Biol Chem (2004) 1.35
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther (2003) 1.32
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A (2006) 1.28
Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res (2008) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (2007) 1.28
Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol (2005) 1.27
Current strategies to target p53 in cancer. Biochem Pharmacol (2010) 1.26
Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol (2008) 1.25
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Restoring p53-dependent tumor suppression. Cancer Biol Ther (2003) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics (2012) 1.22
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res (2004) 1.22
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther (2007) 1.22
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res (2006) 1.20
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (2009) 1.18
The depolarization - attenuated backscatter relation: CALIPSO lidar measurements vs. theory. Opt Express (2007) 1.17
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther (2006) 1.16
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol (2011) 1.15
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet (2003) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer (2012) 1.11
House dust extracts have both TH2 adjuvant and tolerogenic activities. J Allergy Clin Immunol (2006) 1.10
Hydropathic complementarity determines interaction of epitope (869)HITDTNNK(876) in Manduca sexta Bt-R(1) receptor with loop 2 of domain II of Bacillus thuringiensis Cry1A toxins. J Biol Chem (2002) 1.10
Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A (2004) 1.10
p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res (2006) 1.09
Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol (2008) 1.08